Yes, Synarel (nafarelin acetate) is FDA-approved for treating endometriosis.[1]
How Synarel treats endometriosis
Synarel is a GnRH agonist nasal spray that suppresses ovarian estrogen production, shrinking endometrial implants and reducing pain. Adults use 2 sprays (400 mcg) per nostril daily for 6 months, often followed by progestin therapy to prevent bone loss.[1][2]
Who qualifies for Synarel treatment
It's indicated for women with confirmed endometriosis and symptoms like pelvic pain, dysmenorrhea, or dyspareunia. Not for precocious puberty in children or long-term use beyond 6 months due to risks.[1]
Common side effects patients report
Hot flashes (60-90%), headaches (30-50%), vaginal dryness, decreased libido, and emotional changes occur as estrogen drops. Bone density loss is a concern with extended use.[1][2]
How it compares to Lupron or Orilissa
Synarel offers similar GnRH suppression to Lupron injections but via daily nasal spray, with potentially milder initial flare. Orilissa (elagolix) is oral and dose-adjustable, avoiding full shutdown. All limit use to 6 months.[2]
When treatment ends and what happens next
Therapy stops after 6 months; symptoms may recur in 50% within a year. Alternatives include surgery, birth control, or NSAIDs. No active patents listed on DrugPatentWatch.com; generics available.[1][3]
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019490s030lbl.pdf
[2] https://www.uptodate.com/contents/endometriosis-treatment-overview
[3] https://www.drugpatentwatch.com/p/tradename/SYNAREL